New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCardiogen vs PE-22-28

Cardiogen vs PE-22-28

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cardiogen
Cognitive Enhancement
PE-22-28
Summary
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
Half-Life
Short (minutes); gene-regulatory effects persist longer
Relatively short; CNS effects may persist due to neurogenic mechanisms
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
200–400 mcg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
  • Rapid-onset antidepressant effects (within 24 hours)
  • Promotes hippocampal neurogenesis
  • Improves cognitive performance and memory
  • Reduces anxiety and depressive behavior
  • Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
  • May help treatment-resistant depression
  • Neuroprotective effects
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
  • Generally well tolerated in animal models
  • Limited human data available
  • Possible mild headache or transient mood changes at initiation
  • Injection site reactions (SC)
Stacks With